Atsena Reports Lighthouse Responses For ATSN-201, Setting Up A 2028 XLRS Filing Plan
The Catalyst Brief
Coverage
Biotech Innovation
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Latest
Cerevance Revives Solengepras With Phase 3 Parkinson’s Win, After Last Year’s Midstage Miss
The Catalyst Brief
MimiVax Misses Phase 2 Glioblastoma Goal With SurVaxM, But Points To Benefit In Younger Subset
The Catalyst Brief
Nuvig Halts NVG-2089 CIDP Trial, Keeping Midstage ITP Study Running
The Catalyst Brief
Most read
Ai3Bio Unveils $48 Million Financing, Targets Th17 Cells With cGAS-STING mRNA Approach
The Catalyst Brief
Oct 5, 2026
Deisseroth, Hegemann And Nagel Win 2026 Nobel Prize In Medicine For Optogenetics
The Catalyst Brief
Science Spotlights Menopause And Pain In Women’s Health Issue, Exposing How Much Research Still Lags
The Catalyst Brief
Amgen Details Daxdilimab Lupus Phase 2 Win With 6-Point CLASI-A Reduction
The Catalyst Brief
More in this beat
Oct 7, 2026ArriVent Misses Phase 3 PFS Goal For Firmonertinib In 398-Patient NSCLC Trial, Sending Shares Down 57%
The study tested two doses of firmonertinib against platinum-based chemotherapy in 398 patients with non-squamous, locally advanced or metastatic non-small cell lung cancer. While the high dose improved response rate and showed stronger investigator-assessed PFS, the prespecified primary readout by BICR fell short.
The Catalyst Brief
Deisseroth, Hegemann And Nagel Win 2026 Nobel Prize In Medicine For Optogenetics
The Nobel committee honored work that identified channelrhodopsin and then adapted it to switch selected neurons on and off with light in living brains. The prize highlights how a basic-science finding in algae became a widely used method for mapping how specific cells shape behavior, memory and disease-relevant circuitry.
The Catalyst Brief
Oct 5, 2026Vaxcyte Posts Phase 3 VAX-31 Win Against Prevnar 20 And Capvaxive, Setting Up A 2028 FDA Filing
In the phase 3 Opus-1 study, VAX-31 showed non-inferiority on all 20 strains targeted by Prevnar 20 and 17 of the 19 serotypes targeted by Capvaxive. The two misses against Capvaxive still cleared a lower historical non-inferiority threshold, leaving Vaxcyte with a competitive dataset in a market where serotype coverage tradeoffs define product positioning.
The Catalyst Brief
Oct 5, 2026Ai3Bio Unveils $48 Million Financing, Targets Th17 Cells With cGAS-STING mRNA Approach
The startup is combining lipid nanoparticle delivery, messenger RNA, a CD161-targeting antibody and the cGAS-STING pathway in an effort to create a more selective immunology therapy. Its pitch is that precision depletion of disease-driving cells could avoid some tradeoffs associated with broader immune reset approaches and cell therapies.
The Catalyst Brief
Mary-Claire King Described BRCA Work’s Reach As Nobel Speculation Returns Ahead Of This Year’s Prize
Ahead of this year’s Nobel announcements, geneticist Mary-Claire King reflected on a long period of being mentioned as a possible winner and on the work that put her in that conversation. King’s identification of hereditary breast and ovarian cancer risk linked to BRCA1 and BRCA2 helped create actionable prevention pathways that she said have saved thousands of women from cancer mortality.
The Catalyst Brief
Oct 2, 2026Science Spotlights Menopause And Pain In Women’s Health Issue, Exposing How Much Research Still Lags
The package arrives amid political attacks on women’s rights and health care and funding cuts affecting this area of research, according to the editors. Its deeper message is that women’s health is still often funded and studied too narrowly, leaving basic questions unresolved even in conditions with a large patient burden.
The Catalyst Brief
Sep 30, 2026Merck Posts 72% HiSCR50 With High-Dose Tulisokibart, Extending TL1A Into HS
The randomized, double-blind, placebo-controlled study enrolled 149 patients with moderate to severe hidradenitis suppurativa. The key industry signal is portfolio breadth: Merck now has support for moving tulisokibart into Phase 3 in HS even after mixed readouts in other inflammatory diseases.
The Catalyst Brief
Sep 30, 2026Amgen Details Daxdilimab Lupus Phase 2 Win With 6-Point CLASI-A Reduction
Amgen’s abstract and presentation at the European Academy of Dermatology and Venereology Congress in Milan add specificity to a result the company had previously described only in broad terms. For a company that had seen daxdilimab fail in systemic lupus erythematosus and had dropped two internal midstage lupus programs for futility, the discoid lupus signal matters less as a broad lupus comeback than as evidence that a narrower dermatology indication may still support the asset.
The Catalyst Brief
Sep 30, 2026Researchers Cut Brain Tissue Loss 40% In Tauopathy Mice By Blocking CXCR3-Linked T Cell Entry
The study, published in Neuron, used an antibody to block CXCR3 in mice modeling Alzheimer’s disease and other tauopathies. Treated animals showed less brain tissue loss and better performance on standard memory tests even though tau levels were similar between treated and untreated groups.
The Catalyst Brief
Sep 29, 2026Maui Study Finds Antimony Nearly 40 Times Higher After Wildfires, Extending Air-Quality Risks Beyond The Fire
Research published in the Proceedings of the National Academy of Sciences suggests the aftermath of the 2023 Maui wildfires left nearby residents exposed to metal mixtures associated with respiratory harm long after the burning stopped. The work adds evidence that climate-related disasters can create chronic exposure pathways through burned buildings, vehicles, electronics and contaminated residue, not just vegetation smoke.
The Catalyst Brief
Sep 28, 2026Kodiak Matches Eylea In Phase 3 With Zenkuda, Reopening An FDA Path After Its 2023 Setback
The DAYBREAK study put two Kodiak candidates against aflibercept in wet age-related macular degeneration and met the primary endpoint on vision gains at one year. The more immediate commercial readthrough centers on zenkuda, where Kodiak is pitching Eylea-like efficacy with longer intervals between treatments for many patients.
The Catalyst Brief
Sep 28, 2026Adicet Bio Reports 12 Lupus Remissions With Prula-Cel, As Autoimmune CAR-T Safety Stays In Focus
One year after treatment, 12 of 22 evaluated patients had achieved remission of lupus symptoms, and eight of 16 patients with lupus nephritis had remission of kidney symptoms. The readout gives Adicet a differentiated position in autoimmune CAR-T as recent safety events have disrupted competing CD19 programs.
The Catalyst Brief
Other beats
AI in Drug Discovery
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Biopharmaceutical Industry
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Healthcare Investment
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Medical Technology
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Regulatory & Policy
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.